Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

1. Geron Corporation received EC marketing authorization for RYTELO® in treating TD anemia. 2. This approval targets patients with low to intermediate risk myelodysplastic syndromes.

Corporate Developments

2m saved

Insight

Article

FAQ

Why Very Bullish?

The marketing authorization is a significant milestone for GERN. Previous approvals in similar scenarios have led to stock price surges.

How important is it?

The approval by the EC is crucial and directly impacts GERN's market positioning and revenue potential. It enhances investor interest and may lead to further collaborations.

Why Short Term?

Immediate effects are expected as the market reacts to the approval news. Historically, such authorizations lead to quick investor confidence and price movements.

Related Companies

AMGN BMY ABBV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, today announced that the European Commission (EC) has granted marketing authorization for RYTELO® (imetelstat) as a monotherapy for the treatment of adult patients with transfusion-dependent (TD) anemia due to very low, low or intermediate risk myelodysplastic syndromes (lower-risk MDS or LR-MDS) without an isolated d.

Geron Announces European Commission Approval of RYTELO® (imetelstat), a First-in-Class Telomerase Inhibitor, for the Treatment of Adults With Transfusion-Dependent Anemia Due to Lower-Risk MDS

FAQ

Why Very Bullish?

How important is it?

Why Short Term?

Related Companies

Related News